N3 alkylated benzimidazole derivatives as MEK inhibitors
US7425637B2 · kind B2 · utility
13Cited by
15References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 18, 2005 |
| Grant date | Sep 16, 2008 |
| Priority date | — |
| Expiry date | Mar 7, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are compounds of the Formula Iand pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.